The company highlighted that as of March 30, 2026, it had unaudited cash, cash equivalents, and marketable securities totaling $54.9 million, providing a financial runway into 2027. Unicycive is currently preparing for the potential commercial launch of its investigational oral phosphate binder, oxylanthanum carbonate (OLC), which is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026. The company is actively engaged in commercial readiness activities in anticipation of a potential launch in the third quarter of 2026.
CEO Shalabh Gupta emphasized the pivotal nature of the year for Unicycive, noting the FDA's acceptance of the NDA resubmission for OLC and the potential for approval and launch later this year. He stated, "With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders." The company is also focused on strengthening its commercial infrastructure and advancing market readiness initiatives to support the anticipated launch of OLC.
